CAC
LAB icon

Cowen and Company’s Standard BioTools LAB Stock Holding History

Cowen and Company’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-274,420
Closed -$530K – 173
2024
Q3 		$530K Hold
274,420
– – 0.02% 179
2024
Q2 		$486K Hold
274,420
– – 0.01% 180
2024
Q1 		$744K Buy
+274,420
New +$662K 0.03% 174

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Cowen and Company's LAB Position: Q4 2024 in Review

Cowen and Company sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 274,420 shares — an estimated $530K sold.

Cowen and Company first reported a position in LAB in Q1 2024 and held it in 3 quarters. The position peaked at $744K in Q1 2024. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Cowen and Company reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 274,420 Standard BioTools shares in Q4 2024, an estimated $530K.
  • Cowen and Company first reported a position in Standard BioTools in Q1 2024 and held it in 3 quarters.
  • Cowen and Company's Standard BioTools position peaked at $744K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.